Learning, Predicting, and Interpreting Omics Data with Biologically Informed Models

Why It Matters

Integrating mechanistic knowledge with omics data accelerates discovery of actionable targets, crucial for overcoming drug resistance and improving precision medicine. The approach also raises the interpretability bar for AI models in biomedical research.

Key Takeaways

• CORNETO integrates prior knowledge with omics via constrained optimization
• Used in EU DECIDER project to uncover ovarian cancer chemo resistance mechanisms
• Convex CORNETO problems become hard inductive biases for neural networks
• Virtual Cell Challenge benchmarks reveal strengths and gaps of perturbation models
• Biologically informed models improve interpretability and actionable insights from high‑dimensional data

Pulse Analysis

The explosion of high‑throughput omics technologies has outpaced our ability to translate raw measurements into mechanistic insight. Traditional statistical models struggle with sparse experimental conditions, batch effects, and confounding variables, often yielding correlations without causal clarity. By embedding curated pathway maps and protein‑protein interaction graphs directly into the learning objective, frameworks like CORNETO shrink the hypothesis space, allowing algorithms to focus on biologically plausible solutions. This synergy between data‑driven inference and expert knowledge not only boosts predictive accuracy but also produces network structures that researchers can interrogate for hypothesis generation.

In practice, CORNETO’s constrained optimization has been deployed within the EU‑funded DECIDER consortium to dissect chemotherapy resistance in high‑grade serous ovarian cancer. By aligning transcriptomic profiles with a curated knowledge graph, the team identified a set of transcription factors and signaling cascades that mediate drug evasion, offering potential biomarkers for patient stratification. The convex variants of CORNETO further enable seamless integration as fixed layers in deep neural networks, acting as hard inductive biases that enforce biologically realistic relationships during training. This hybrid architecture bridges the gap between black‑box AI and transparent mechanistic modeling, a critical step for regulatory acceptance in clinical settings.

Benchmarking efforts such as the 1st Virtual Cell Challenge have provided a community‑wide stress test for these approaches. Participants leveraging biologically informed models achieved top‑tier performance in predicting perturbation outcomes, yet the competition also highlighted persistent challenges, including scalability to multi‑omics integration and handling of unseen perturbations. As the field moves toward increasingly complex datasets—single‑cell multi‑omics, spatial transcriptomics—the lessons from CORNETO and related competitions underscore the need for scalable, interpretable frameworks that can harness prior knowledge without stifling discovery. Continued investment in such hybrid methods promises to accelerate translational pipelines from bench to bedside.